View ValuationDarwin 将来の成長Future 基準チェック /56Darwin利益と収益がそれぞれ年間123%と25.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に7.4% 121.8%なると予測されています。主要情報123.0%収益成長率121.85%EPS成長率Biotechs 収益成長21.1%収益成長率25.8%将来の株主資本利益率7.40%アナリストカバレッジLow最終更新日21 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • 59mDarwin AG, Annual General Meeting, Jun 26, 2026Darwin AG, Annual General Meeting, Jun 26, 2026, at 13:30 W. Europe Standard Time.New Risk • May 16New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.4m (US$107.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. High level of non-cash earnings (53% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (0.9% net profit margin). Market cap is less than US$100m (€92.4m market cap, or US$107.4m).Reported Earnings • May 15Full year 2025 earnings released: EPS: €0.045 (vs €1.54 in FY 2024)Full year 2025 results: EPS: €0.045 (down from €1.54 in FY 2024). Revenue: €61.6m (up 125% from FY 2024). Net income: €545.5k (down 97% from FY 2024). Profit margin: 0.9% (down from 68% in FY 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.Valuation Update With 7 Day Price Move • Mar 06Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €8.00, the stock trades at a forward P/E ratio of 29x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 6.6% over the past three years.お知らせ • Feb 26Darwin AG to Report Fiscal Year 2025 Results on May 12, 2026Darwin AG announced that they will report fiscal year 2025 results on May 12, 2026Valuation Update With 7 Day Price Move • Feb 19Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to €9.15, the stock trades at a forward P/E ratio of 33x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 21% over the past three years.Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €9.75, the stock trades at a forward P/E ratio of 35x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total returns to shareholders of 20% over the past three years.New Risk • Jan 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 49% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 49% per year for the foreseeable future. Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €7.65, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 10% over the past three years.Valuation Update With 7 Day Price Move • Oct 09Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €6.60, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 19x in the Biotechs industry in Europe. Total loss to shareholders of 13% over the past three years.分析記事 • Jul 06Darwin AG's (MUN:7V0) Price Is Right But Growth Is LackingWith a price-to-sales (or "P/S") ratio of 3.2x Darwin AG ( MUN:7V0 ) may be sending bullish signals at the moment...お知らせ • May 21+ 1 more updateDarwin AG, Annual General Meeting, Jun 27, 2025Darwin AG, Annual General Meeting, Jun 27, 2025, at 13:30 W. Europe Standard Time.New Risk • Aug 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €84.6m (US$91.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risk Market cap is less than US$100m (€84.6m market cap, or US$91.3m).お知らせ • May 14Darwin AG, Annual General Meeting, Jun 18, 2024Darwin AG, Annual General Meeting, Jun 18, 2024, at 11:00 W. Europe Standard Time.業績と収益の成長予測MUN:7V0 - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028137N/A-11N/A212/31/2027897-143212/31/2026590-17-3112/31/2025621-22-13N/A12/31/20242718-29-25N/A12/31/2023180-20-19N/A12/31/2022210459395N/A12/31/2021133231112N/Aアナリストによる今後の成長予測収入対貯蓄率: 7V0の予測収益成長率 (年間123% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: 7V0の収益 ( 123% ) はGerman市場 ( 16.9% ) よりも速いペースで成長すると予測されています。高成長収益: 7V0の収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: 7V0の収益 ( 25.8% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: 7V0の収益 ( 25.8% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 7V0の 自己資本利益率 は、3年後には低くなると予測されています ( 7.4 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 19:30終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Darwin AG 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Cosmin FilkerGBC AGKlaus BreitenbachODDO BHF Corporate & Markets
お知らせ • 59mDarwin AG, Annual General Meeting, Jun 26, 2026Darwin AG, Annual General Meeting, Jun 26, 2026, at 13:30 W. Europe Standard Time.
New Risk • May 16New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.4m (US$107.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. High level of non-cash earnings (53% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (0.9% net profit margin). Market cap is less than US$100m (€92.4m market cap, or US$107.4m).
Reported Earnings • May 15Full year 2025 earnings released: EPS: €0.045 (vs €1.54 in FY 2024)Full year 2025 results: EPS: €0.045 (down from €1.54 in FY 2024). Revenue: €61.6m (up 125% from FY 2024). Net income: €545.5k (down 97% from FY 2024). Profit margin: 0.9% (down from 68% in FY 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
Valuation Update With 7 Day Price Move • Mar 06Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €8.00, the stock trades at a forward P/E ratio of 29x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 6.6% over the past three years.
お知らせ • Feb 26Darwin AG to Report Fiscal Year 2025 Results on May 12, 2026Darwin AG announced that they will report fiscal year 2025 results on May 12, 2026
Valuation Update With 7 Day Price Move • Feb 19Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to €9.15, the stock trades at a forward P/E ratio of 33x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 21% over the past three years.
Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €9.75, the stock trades at a forward P/E ratio of 35x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total returns to shareholders of 20% over the past three years.
New Risk • Jan 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 49% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 49% per year for the foreseeable future. Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).
Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €7.65, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 10% over the past three years.
Valuation Update With 7 Day Price Move • Oct 09Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €6.60, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 19x in the Biotechs industry in Europe. Total loss to shareholders of 13% over the past three years.
分析記事 • Jul 06Darwin AG's (MUN:7V0) Price Is Right But Growth Is LackingWith a price-to-sales (or "P/S") ratio of 3.2x Darwin AG ( MUN:7V0 ) may be sending bullish signals at the moment...
お知らせ • May 21+ 1 more updateDarwin AG, Annual General Meeting, Jun 27, 2025Darwin AG, Annual General Meeting, Jun 27, 2025, at 13:30 W. Europe Standard Time.
New Risk • Aug 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €84.6m (US$91.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risk Market cap is less than US$100m (€84.6m market cap, or US$91.3m).
お知らせ • May 14Darwin AG, Annual General Meeting, Jun 18, 2024Darwin AG, Annual General Meeting, Jun 18, 2024, at 11:00 W. Europe Standard Time.